



**AMENDED CHARTER**  
**NATIONAL CANCER INSTITUTE**  
**DIRECTOR'S CONSUMER LIAISON GROUP**

**AUTHORITY**

42 U.S.C. 285a-2(b)(7), section 413(b)(7) of the Public Health Service Act, as amended. The National Cancer Institute Director's Consumer Liaison Group (Committee) is governed by the provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), which sets forth standards for the formation and use of advisory committees.

**MEMBERSHIP AND DESIGNATION**

The Committee will consist of 12 to 16 members, including the Chair appointed by the Director, NCI. The membership will consist of consumer advocates who are involved in the cancer experience and possess an expert understanding of non-scientific burdens to cancer research as well as of the perspectives and dynamics of the research, patient, policy, and advocacy communities interested in cancer research and cancer care delivery. This expert understanding will have been gained through experience working in the cancer consumer advocacy field, affiliation with a cancer related professional society, affiliation with a research foundation involved in cancer research or healthcare, experience as a health care professional focused on the of study cancer and other related diseases, or experience serving as a thought-leader in an area related to cancer research and care delivery. All non-Federal members serve as Special Government Employees. A quorum for the conduct of business by the full Committee will consist of a majority of currently appointed members. Members and the Chair will be invited to serve for overlapping four-year terms. A member may serve after the expiration of that member's term until a successor has taken office.

**DESCRIPTION OF DUTIES**

The Committee makes recommendations on issues and challenges facing the Institute, at the request of the Director, NCI. Committee members will provide informed, non-scientific perspectives relevant to promoting research outcomes that are in the best interest of cancer patients. This includes identifying new approaches, promoting innovation, and recognizing unforeseen risks or barriers. Additionally, committee members will identify unintended consequences that could result from NCI decisions or actions as well as enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders, in the interest of meeting common Institute and community goals.

## **ESTIMATED NUMBER AND FREQUENCY OF MEETINGS**

Meetings of the full Committee will be held approximately 3 times within a fiscal year. Meetings will be open to the public except as determined otherwise by the Secretary of Health and Human Services (Secretary) in accordance with subsection (c) of section 552b of Title 5 U.S.C. Notice of all meetings will be given to the public. In the event a portion of a meeting is closed to the public, as determined by the Secretary, in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act, a report will be prepared which will contain, as a minimum, a list of members and their business addresses, the Committee's functions, dates and places of meetings, and a summary of the Committee's activities and recommendations made during the fiscal year. A copy of the report shall be provided to the Department Committee Management Officer.